Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$12.56 USD

12.56
2,263,426

+0.25 (2.03%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $12.56 0.00 (0.00%) 5:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of +4.65% and +5.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IART Stock May Rise on First Enrollment in AERA Pediatric Registry

by Zacks Equity Research

Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.

Zacks Equity Research

Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Integra (IART) Up 2.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is the Options Market Predicting a Spike in Integra LifeSciences Stock?

by Zacks Equity Research

Investors need to pay close attention to Integra LifeSciences stock based on the movements in the options market lately.

Zacks Equity Research

Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut

by Zacks Equity Research

IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak.

Zacks Equity Research

Compared to Estimates, Integra (IART) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Integra LifeSciences (IART) Q1 Earnings Miss Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of -4.65% and 0.13%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Integra (IART) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Integra (IART) stock based on the movements in the options market lately.

Zacks Equity Research

Integra (IART) Down 7.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is This the Right Time to Hold Integra Stock in Your Portfolio?

by Zacks Equity Research

IART stays on investors' radar courtesy of its strong prospects in the CSS segment and international growth.

Zacks Equity Research

Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up

by Zacks Equity Research

IART delivers better-than-expected earnings in the fourth quarter of 2024.

Zacks Equity Research

Integra (IART) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Integra LifeSciences (IART) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 14.12% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IART vs. SONVY: Which Stock Is the Better Value Option?

by Zacks Equity Research

IART vs. SONVY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Integra LifeSciences (IART) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zacks.com featured highlights include General Motors, Integra, The Greenbrier, TPG RE Finance and Enersys

by Zacks Equity Research

General Motors, Integra, The Greenbrier, TPG RE Finance and Enersys have been highlighted in this Investment Ideas article.

Kinjel Shah headshot

5 Price-to-Book Value Stocks With Great Prospects

by Kinjel Shah

The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, IART, GBX, TRTX and ENS are some such stocks.

Sumit Singh headshot

4 Intriguing Value Stocks to Add to Your Portfolio Now

by Sumit Singh

Value investing is essentially about selecting cheap but fundamentally sound stocks. TSN, GM, IART and ENS boast low P/CF ratios.

Zacks Equity Research

IART or PEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

IART vs. PEN: Which Stock Is the Better Value Option?

Sumit Singh headshot

Invest in These 4 Value Stocks for Promising 2025 Returns

by Sumit Singh

Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, GM, MGNI & IART boast a low P/CF ratio.

Zacks Equity Research

Is Integra LifeSciences (IART) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Implied Volatility Surging for Integra LifeSciences (IART) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Integra LifeSciences (IART) stock based on the movements in the options market lately.

Zacks Equity Research

Here's Why You Should Hold IART Stock in Your Portfolio Now

by Zacks Equity Research

Integra's growth within its Tissue Technologies business segment bolsters investors' confidence in the stock.